Home > Neurology > ECTRIMS 2019 > Monitoring and Treatment of Progressive MS > Transplantation of autologous mesenchymal stem cells

Transplantation of autologous mesenchymal stem cells

Expert
Prof. Dimitrios Karussis, Hebrew University of Jerusalem, Israel
Conference
ECTRIMS 2019

Mesenchymal stem cells (MSCs) induce both immune-modulatory and neurotrophic effects, and are safe when administered to patients with MS or amyotrophic lateral sclerosis (ALS). The current phase 2b double blind randomised trial, presented by Prof. Dimitrios Karussis (Hebrew University of Jerusalem, Israel), evaluated the safety and efficacy of transplantation of autologous bone marrow-derived MSCs in patients with active progressive MS. Furthermore, this study evaluated the optimal route of administration of MSCs, comparing intrathecal to intravenous administration [1].

This trial enrolled 48 patients with progressive MS (EDSS range: 3.5-6.5). The participants randomly received autologous MSCs or placebo via intrathecal or intravenous administration. At 6 months, treatment groups were crossed over, and patients re-treated with either MSC or placebo.

Per-protocol analysis of the pre-determined primary endpoint showed that significantly fewer patients...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on